Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metropolis HealthcareNSE:METROPOLIS -5.73%93 Gross Margin % is 80.51% as of Mar. 2026, which is 5% above its 10-year median of 76.39. GuruFocus rates NSE:METROPOLIS with a GF Score™ of 93/100 and a GF Value™ of ₹591.34 (Fairly Valued). The stock has 4 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Metropolis Healthcare ranks better than 85.05% on this metric.
NSE:METROPOLIS's Gross Margin % is ranked better than 85.05% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 51.14
vs NSE:METROPOLIS: 78.89
Metropolis Healthcare had a gross margin of 80.51% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Metropolis Healthcare was 1.30% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Metropolis Healthcare had a gross margin of 80.51% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Metropolis Healthcare Gross Margin % Related Terms
Metropolis Healthcare Gross Margin % Historical Data
* Premium members only.
The historical data trend for Metropolis Healthcare's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:METROPOLIS vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Metropolis Healthcare's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metropolis Healthcare Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Metropolis Healthcare's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Metropolis Healthcare's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Metropolis Healthcare (NSE:METROPOLIS) has a Gross Margin % of 80.51% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Metropolis Healthcare and its competitors. This is near median its historical median of 76.39. Over the past decade, Metropolis Healthcare's Gross Margin % has ranged from 73.92 to 79.05. According to the industry distribution chart, Metropolis Healthcare ranks #29 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 14.9%.
Is Metropolis Healthcare's Gross Margin % too high?
Metropolis Healthcare's current Gross Margin % of 80.51% is near median its 10-year median of 76.39. Over the past 10 years, this metric has ranged from a low of 73.92 to a high of 79.05. The Medical Diagnostics & Research industry median Gross Margin % is 51.14. Metropolis Healthcare's value of 80.51% is 57.4% above this industry median. Based on the distribution chart, Metropolis Healthcare ranks #29 out of 194 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Metropolis Healthcare has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Metropolis Healthcare ranks #29 out of 194 companies for Gross Margin %. This places Metropolis Healthcare in the top 15% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 51.14. Metropolis Healthcare's value of 80.51% is 57.4% above this benchmark. Historically, Metropolis Healthcare's own Gross Margin % has ranged from 73.92 to 79.05 over the past decade. While the company's 10-year median is 76.39 vs. the industry median of 51.14, Metropolis Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 51.14, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metropolis Healthcare's current Gross Margin % of 80.51% is 57.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Metropolis Healthcare and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 51.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metropolis Healthcare's current Gross Margin % is 80.51%, which is near median its own 10-year median of 76.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹591.34, compared to a current price of ₹545.30 — trading 7.8% below its estimated fair value. The current Gross Margin % is 80.51%, which is near median its 10-year median of 76.39 and 57.4% above the Medical Diagnostics & Research industry median of 51.14. Metropolis Healthcare's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current Gross Margin % is 80.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?
Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued.
The current stock price of ₹545.30 is trading 7.8% below its estimated GF Value™ of ₹591.34.
GuruFocus considers Metropolis Healthcare to be Fairly Valued.
Key valuation signals for NSE:METROPOLIS:
Gross Margin %: 80.51% (near median its 10-year median of 76.39)
GF Value™: ₹591.34 vs. price of ₹545.30 (7.8% below fair value)
Industry Position: 57.4% above the Medical Diagnostics & Research median (#29 of 194)
No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
93GF Score
Get the complete analysis for NSE:METROPOLIS
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:METROPOLIS has been successfully added to your 
